Dose Ranging Trial of Tipranavir/Ritonavir in Treatment-Experienced HIV Infected Individuals

PHASE2CompletedINTERVENTIONAL
Enrollment

165

Participants

Timeline

Start Date

April 30, 2002

Study Completion Date

October 31, 2002

Conditions
HIV Infections
Interventions
DRUG

Protease inhibitor tipranavir

Trial Locations (51)

10029

Mount Sinai School of Medicine, New York

11794

University of New York at Stony Brook, Stony Brook

12208

Albany Medical College, Albany

20007

Georgetown University Medical Center, Washington D.C.

20009

Dupont Circle Physicians Group, Washington D.C.

21205

John's Hopkins University School of Medicine, Baltimore

22003

Infectious Disease Physicians Research, Annandale

27157

Wake Forest University Baptist Medical Center, Winston-Salem

27599

University of North Carolina, Chapel Hill

27710

Duke University Medical Center Infectious Diseases Clinic, Durham

28078

Jemsek Clinic, Huntersville

29206

Burnside Clinic, Columbia

30033

Atlanta VA Medical Center, Dept. of ID, Decatur

30308

AIDS Research Consortium of Atlanta, Atlanta

31207

Mercer University School of Medicine, Macon

32701

(IDC) Research Institute, Altamonte Springs

32960

Treasure Coast Infectious Disease Consultants, Vero Beach

33133

Steinhart Medical Associates, South Miami

33136

Jackson Medical Tower, Miami

33308

Therafirst Medical Center, Fort Lauderdale

33602

Hillsborough County Health Dept., Tampa

37203

Vanderbilt University - AIDS Clinical Trial Unit, Nashville

40202

University of Louisville, Louisville

43210

Ohio State University Medical Center, Columbus

48109

University of Michigan Health System, Ann Arbor

48202

Henry Ford Hospital, Infectious Diseases Dept., Detroit

60612

CORE Center, Cook County Hospital, Chicago

Rush Presbyterian/St. Luke's Medical Center, Chicago

63108

Washington University AIDS Clinical Trial Unit, St Louis

64111

Kansas City Free Health Clinic, Kansas City

70112

HIV Outpatient Program (H.O.P.), New Orleans

73104

Infect. Disease Institute, Clinical Trials Unit, Oklahoma City

75219

Nelson-Tebedo Clinic, Dallas

77004

Gathe Clinic, Houston

85006

Phoenix Body Positive, Phoenix

89102

Wellness Center, Las Vegas

90027

AHF Research Center, Los Angeles

90033

University of So. California / LA County USC Medical Center, Los Angeles

90046

ID Care, Inc., Los Angeles

90048

Tower I.D. Medical Assoc., Inc., Los Angeles

90095

University of California, Los Angeles Medical Center, Los Angeles

90813

Living Hope Clinical Trials Inc., Long Beach

92708

Orange County Center for Special Immunology, Fountain Valley

94110

University of California San Francisco Positive Health Program Research, San Francisco

94115

Pacific Horizon Medial Group, San Francisco

97505

Southwest CARE Center, Santa Fe

02125

Community Research Initiative of New England, Boston

01107

CRI Community Research Initiative, Springfield

08844

ID Care, Inc., Hillsborough

07869

ID Care, Inc., Randolph Township

00923

Clinical Research Puerto Rico, San Juan

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT00034866 - Dose Ranging Trial of Tipranavir/Ritonavir in Treatment-Experienced HIV Infected Individuals | Biotech Hunter | Biotech Hunter